Agreement - August 4, 2017
BioInvent and ThromboGenics amend agreement
BioInvent International and ThromboGenics NV announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The revisions to the existing agreement have been aligned with each company’s strategic ambitions and therapeutic focus. The novel anti-PIGF monoclonal antibody is currently being developed […]
Clinical Trials - January 12, 2017
ThromboGenics initiates Phase II study
BioInvent’s collaboration partner ThromboGenics initiates Phase II study with the drug candidate THR-317. BioInvent International AB announces today that the company’s collaboration partner ThromboGenics NV reports that the first patients have been enrolled in a study with the drug candidate THR-317 for the treatment of diabetic macular oedema. The study evaluates safety and efficacy of […]